The approval and commercialization of Oxervate (cenegermin-bkbj, Dompé) in the United States has improved our ability to treat corneal persistent epithelial defects (PEDs) or corneal ...

Investigators recommend a dose of 0.2 mg/mL losartan 6 times per day for patients with a current corneal epithelial defect. Topical losartan for the treatment of scarring corneal fibrosis mediated by ...

Lufepirsen is under clinical development by Amber Ophthalmics and currently in Phase II for Persistent Corneal Epithelial Defects. According to GlobalData, Phase II drugs for Persistent Corneal ...

METHODS 10 consecutive patients who underwent AMT were included. The indications were: group A, cases with persistent epithelial defect after corneal abscess (n=1), radiation (n=1), or chemical burn ...

Eyes were further grouped according to Mackie's classification [24] into stage 1: neurotrophic keratopathy with punctate staining, vascularization, or scarring but no epithelial defect ...

On the left eye, the patient had conjunctival congestion and hyperemia, a central 2- × 2-mm corneal epithelial defect with deep stromal infiltration, endothelial plaque, moderate anterior chamber ...

Kala Pharmaceuticals Inc (NASDAQ:KALA)., a micro-cap biotech company valued at $40.13 million, has seen its stock reach a 52-week high, hitting an impressive $8.81. This peak reflects a significant ...

A persistent increase in TNF-α in colonic mucosa may contribute to the epithelial barrier defects associated with abdominal pain in quiescent IBD, but not in IBS. Optimisation of anti-inflammatory ...

These alterations led to dysfunction of the epithelial barrier and invasion of commensal bacteria into the mucosa. Conclusions A defect in ClC-3 may contribute to the pathogenesis of IBD by promoting ...

Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec H2X 0A9, Canada ...